APO Research
Talk to an analyst

APO RESEARCH · REPORT

BCMA-targeted CAR-T Cell Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global BCMA-targeted CAR-T Cell Therapy Market Outlook and Growth Opportunities 2026

26 December 2025197 pages

Choose your research edition.

Industry ResearchBCMA-targeted CAR-T Cell Therapy Industry Research Report 2026103 pages · $2,950 USDIndustry Growth & TrendsGlobal BCMA-targeted CAR-T Cell Therapy Industry Growth and Trends Forecast to 203262 pages · $3,450 USDMarket StructureGlobal BCMA-targeted CAR-T Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal BCMA-targeted CAR-T Cell Therapy Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal BCMA-targeted CAR-T Cell Therapy Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global BCMA-targeted CAR-T Cell Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for BCMA-targeted CAR-T Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for BCMA-targeted CAR-T Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for BCMA-targeted CAR-T Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the BCMA-targeted CAR-T Cell Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the BCMA-targeted CAR-T Cell Therapy market include Nanjing Iaso Biotherapeutics, CARsgen, Nanjing Legend Biotechnology/J&J and Bristol-Myers Squibb (Abecma), among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global BCMA-targeted CAR-T Cell Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of BCMA-targeted CAR-T Cell Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents BCMA-targeted CAR-T Cell Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global BCMA-targeted CAR-T Cell Therapy market.

BCMA-targeted CAR-T Cell Therapy Segment by Company

Nanjing Iaso Biotherapeutics

CARsgen

Nanjing Legend Biotechnology/J&J

Bristol-Myers Squibb (Abecma)

BCMA-targeted CAR-T Cell Therapy Segment by Type

Abecma

Carvykti

Others

BCMA-targeted CAR-T Cell Therapy Segment by Application

Hospital

Oncology Clinic

BCMA-targeted CAR-T Cell Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global BCMA-targeted CAR-T Cell Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the BCMA-targeted CAR-T Cell Therapy key companies, revenue, market share, and recent developments.

3. To split the BCMA-targeted CAR-T Cell Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions BCMA-targeted CAR-T Cell Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify BCMA-targeted CAR-T Cell Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze BCMA-targeted CAR-T Cell Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global BCMA-targeted CAR-T Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of BCMA-targeted CAR-T Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of BCMA-targeted CAR-T Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global BCMA-targeted CAR-T Cell Therapy industry.

Chapter 3: Detailed analysis of BCMA-targeted CAR-T Cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of BCMA-targeted CAR-T Cell Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of BCMA-targeted CAR-T Cell Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. BCMA-targeted CAR-T Cell Therapy Industry Trends Table 2. BCMA-targeted CAR-T Cell Therapy Industry Drivers Table 3. BCMA-targeted CAR-T Cell Therapy Industry Opportunities and Challenges Table 4. BCMA-targeted CAR-T Cell Therapy Industry Restraints Table 5. Global BCMA-targeted CAR-T Cell Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global BCMA-targeted CAR-T Cell Therapy Revenue Share by Company (2021-2026) Table 7. Global BCMA-targeted CAR-T Cell Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global BCMA-targeted CAR-T Cell Therapy Key Company Manufacturing Base & Headquarters Table 9. Global BCMA-targeted CAR-T Cell Therapy Company, Product Type & Application Table 10. Global BCMA-targeted CAR-T Cell Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global BCMA-targeted CAR-T Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Abecma Table 15. Significant Companies of Carvykti Table 16. Significant Companies of Others Table 17. Global BCMA-targeted CAR-T Cell Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global BCMA-targeted CAR-T Cell Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global BCMA-targeted CAR-T Cell Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type (2021-2026) Table 21. Global BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Oncology Clinic Table 24. Global BCMA-targeted CAR-T Cell Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global BCMA-targeted CAR-T Cell Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global BCMA-targeted CAR-T Cell Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application (2021-2026) Table 28. Global BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application (2027-2032) Table 29. Global BCMA-targeted CAR-T Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global BCMA-targeted CAR-T Cell Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global BCMA-targeted CAR-T Cell Therapy Sales Value Share by Region (2021-2026) Table 32. Global BCMA-targeted CAR-T Cell Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global BCMA-targeted CAR-T Cell Therapy Sales Value Share by Region (2027-2032) Table 34. Global BCMA-targeted CAR-T Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global BCMA-targeted CAR-T Cell Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global BCMA-targeted CAR-T Cell Therapy Sales Value Market Share by Country (2021-2026) Table 37. Global BCMA-targeted CAR-T Cell Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global BCMA-targeted CAR-T Cell Therapy Sales Value Market Share by Country (2027-2032) Table 39. Nanjing Iaso Biotherapeutics Company Information Table 40. Nanjing Iaso Biotherapeutics Business Overview Table 41. Nanjing Iaso Biotherapeutics BCMA-targeted CAR-T Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Nanjing Iaso Biotherapeutics BCMA-targeted CAR-T Cell Therapy Product Portfolio Table 43. Nanjing Iaso Biotherapeutics Recent Development Table 44. CARsgen Company Information Table 45. CARsgen Business Overview Table 46. CARsgen BCMA-targeted CAR-T Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. CARsgen BCMA-targeted CAR-T Cell Therapy Product Portfolio Table 48. CARsgen Recent Development Table 49. Nanjing Legend Biotechnology/J&J Company Information Table 50. Nanjing Legend Biotechnology/J&J Business Overview Table 51. Nanjing Legend Biotechnology/J&J BCMA-targeted CAR-T Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Nanjing Legend Biotechnology/J&J BCMA-targeted CAR-T Cell Therapy Product Portfolio Table 53. Nanjing Legend Biotechnology/J&J Recent Development Table 54. Bristol-Myers Squibb (Abecma) Company Information Table 55. Bristol-Myers Squibb (Abecma) Business Overview Table 56. Bristol-Myers Squibb (Abecma) BCMA-targeted CAR-T Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Bristol-Myers Squibb (Abecma) BCMA-targeted CAR-T Cell Therapy Product Portfolio Table 58. Bristol-Myers Squibb (Abecma) Recent Development Table 59. Research Programs/Design for This Report Table 60. Authors List of This Report Table 61. Secondary Sources Table 62. Primary Sources List of Figures Figure 1. BCMA-targeted CAR-T Cell Therapy Product Image Figure 2. Global BCMA-targeted CAR-T Cell Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global BCMA-targeted CAR-T Cell Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global BCMA-targeted CAR-T Cell Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Abecma Image Figure 8. Carvykti Image Figure 9. Others Image Figure 10. Global BCMA-targeted CAR-T Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global BCMA-targeted CAR-T Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Oncology Clinic Image Figure 15. Global BCMA-targeted CAR-T Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global BCMA-targeted CAR-T Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application (2021-2032) Figure 18. Global BCMA-targeted CAR-T Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global BCMA-targeted CAR-T Cell Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America BCMA-targeted CAR-T Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 21. North America BCMA-targeted CAR-T Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe BCMA-targeted CAR-T Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 23. Europe BCMA-targeted CAR-T Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America BCMA-targeted CAR-T Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 27. South America BCMA-targeted CAR-T Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa BCMA-targeted CAR-T Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa BCMA-targeted CAR-T Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Abecma
  • Carvykti
  • Others
Applications
  • Hospital
  • Oncology Clinic
Companies covered
  • Nanjing Iaso Biotherapeutics
  • CARsgen
  • Nanjing Legend Biotechnology/J&J
  • Bristol-Myers Squibb (Abecma)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global BCMA-targeted CAR-T Cell Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global BCMA-targeted CAR-T Cell Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 BCMA-targeted CAR-T Cell Therapy Market Dynamics
  1. 2.1 BCMA-targeted CAR-T Cell Therapy Industry Trends
  2. 2.2 BCMA-targeted CAR-T Cell Therapy Industry Drivers
  3. 2.3 BCMA-targeted CAR-T Cell Therapy Industry Opportunities and Challenges
  4. 2.4 BCMA-targeted CAR-T Cell Therapy Industry Restraints
3 BCMA-targeted CAR-T Cell Therapy Market by Company
  1. 3.1 Global BCMA-targeted CAR-T Cell Therapy Company Revenue Ranking in 2025
  2. 3.2 Global BCMA-targeted CAR-T Cell Therapy Revenue by Company (2021-2026)
  3. 3.3 Global BCMA-targeted CAR-T Cell Therapy Company Ranking (2024-2026)
  4. 3.4 Global BCMA-targeted CAR-T Cell Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global BCMA-targeted CAR-T Cell Therapy Company Product Type and Application
  6. 3.6 Global BCMA-targeted CAR-T Cell Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global BCMA-targeted CAR-T Cell Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 BCMA-targeted CAR-T Cell Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 BCMA-targeted CAR-T Cell Therapy Market by Type
  1. 4.1 BCMA-targeted CAR-T Cell Therapy Type Introduction
  2. 4.1.1 Abecma
  3. 4.1.2 Carvykti
  4. 4.1.3 Others
  5. 4.2 Global BCMA-targeted CAR-T Cell Therapy Sales Value by Type
  6. 4.2.1 Global BCMA-targeted CAR-T Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global BCMA-targeted CAR-T Cell Therapy Sales Value by Type (2021-2032)
  8. 4.2.3 Global BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type (2021-2032)
5 BCMA-targeted CAR-T Cell Therapy Market by Application
  1. 5.1 BCMA-targeted CAR-T Cell Therapy Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Oncology Clinic
  4. 5.2 Global BCMA-targeted CAR-T Cell Therapy Sales Value by Application
  5. 5.2.1 Global BCMA-targeted CAR-T Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global BCMA-targeted CAR-T Cell Therapy Sales Value by Application (2021-2032)
  7. 5.2.3 Global BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application (2021-2032)
6 BCMA-targeted CAR-T Cell Therapy Regional Value Analysis
  1. 6.1 Global BCMA-targeted CAR-T Cell Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global BCMA-targeted CAR-T Cell Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global BCMA-targeted CAR-T Cell Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global BCMA-targeted CAR-T Cell Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America BCMA-targeted CAR-T Cell Therapy Sales Value (2021-2032)
  7. 6.3.2 North America BCMA-targeted CAR-T Cell Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe BCMA-targeted CAR-T Cell Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe BCMA-targeted CAR-T Cell Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific BCMA-targeted CAR-T Cell Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific BCMA-targeted CAR-T Cell Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America BCMA-targeted CAR-T Cell Therapy Sales Value (2021-2032)
  16. 6.6.2 South America BCMA-targeted CAR-T Cell Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa BCMA-targeted CAR-T Cell Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa BCMA-targeted CAR-T Cell Therapy Sales Value Share by Country, 2025 VS 2032
7 BCMA-targeted CAR-T Cell Therapy Country-level Value Analysis
  1. 7.1 Global BCMA-targeted CAR-T Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global BCMA-targeted CAR-T Cell Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global BCMA-targeted CAR-T Cell Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global BCMA-targeted CAR-T Cell Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt BCMA-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt BCMA-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt BCMA-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Nanjing Iaso Biotherapeutics
  2. 8.1.1 Nanjing Iaso Biotherapeutics Company Information
  3. 8.1.2 Nanjing Iaso Biotherapeutics Business Overview
  4. 8.1.3 Nanjing Iaso Biotherapeutics BCMA-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Nanjing Iaso Biotherapeutics BCMA-targeted CAR-T Cell Therapy Product Portfolio
  6. 8.1.5 Nanjing Iaso Biotherapeutics Recent Developments
  7. 8.2 CARsgen
  8. 8.2.1 CARsgen Company Information
  9. 8.2.2 CARsgen Business Overview
  10. 8.2.3 CARsgen BCMA-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CARsgen BCMA-targeted CAR-T Cell Therapy Product Portfolio
  12. 8.2.5 CARsgen Recent Developments
  13. 8.3 Nanjing Legend Biotechnology/J&J
  14. 8.3.1 Nanjing Legend Biotechnology/J&J Company Information
  15. 8.3.2 Nanjing Legend Biotechnology/J&J Business Overview
  16. 8.3.3 Nanjing Legend Biotechnology/J&J BCMA-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Nanjing Legend Biotechnology/J&J BCMA-targeted CAR-T Cell Therapy Product Portfolio
  18. 8.3.5 Nanjing Legend Biotechnology/J&J Recent Developments
  19. 8.4 Bristol-Myers Squibb (Abecma)
  20. 8.4.1 Bristol-Myers Squibb (Abecma) Company Information
  21. 8.4.2 Bristol-Myers Squibb (Abecma) Business Overview
  22. 8.4.3 Bristol-Myers Squibb (Abecma) BCMA-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb (Abecma) BCMA-targeted CAR-T Cell Therapy Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb (Abecma) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst